The Egyptian Journal of Internal Medicine

Table 4 Changes in lipid profile among studied groups

From: The efficacy and safety of niacin on hyperphosphatemia in ESRD patients undergoing hemodialysis: randomized controlled trial

	Niacin group (n = 25)	Control group (n = 25)	P value
Cholesterol (mg/dl)
Baseline	172.40 ± 43.89	179.56 ± 33.78	0.58
At 3rd month	150.52 ± 35.37	184.93 ± 37.19	< 0.001
At 6th month	136.88 ± 32.98	174.25 ± 28.41	< 0.001
HDL (mg/dl)
Baseline	76.56 ± 16.23	80.68 ± 9.30	0.36
At 3rd month	82.44 ± 16.68	77.56 ± 13.56	0.33
At 6th month	82.20 ± 15.01	79.56 ± 14.20	0.57
LDL (mg/dl)
Baseline	93.56 ± 13.99	91.50 ± 13.23	0.64
At 3rd month	86.80 ± 12.60	92.81 ± 9.23	0.10
At 6th month	78.40 ± 14.16	87.81 ± 16.31	0.06
Triglyceride (mg/dl)
Baseline	139.36 ± 35.72	133.93 ± 21.64	0.58
At 3rd month	140.16 ± 42.58	130.12 ± 15.67	0.37
At 6th month	118.08 ± 36.27	125.25 ± 16.89	0.46

Data expressed as mean (SD). P value was significant if < 0.05. HDL high-density lipoprotein, LDL low-density protein

Back to article page